Cited 0 times in
The Effect of ZD 1839 (IressaⓇ) in the Treatment of Refractory Non Small Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세규 | - |
dc.date.accessioned | 2015-07-15T16:53:56Z | - |
dc.date.available | 2015-07-15T16:53:56Z | - |
dc.date.issued | 2003 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/113819 | - |
dc.description.abstract | PURPOSE: The aim of this study was to evaluate the efficacy and the safety of ZD 1839 (IressaⓇ) as a 3rd or 4th line chemotherapy regimen in NSCLC patients who are refractory to a previous chemotherapy regimen. MATERIALS AND METHODS: Twenty-five patients who were refractory to previous chemotherapy were selected for this study. The eligible patients had an ECOG performance status of 0 to 2, and an appropriate end organ function. ZD 1839 (IressaⓇ)250 mg/d was orally administered until the patients experienced disease progression or unacceptable toxicity. RESULTS: Twenty-five patients were analyzed. The median age of the patients was 57 years. The response rate was 12.0% with partial responses in 3 patients. Fourteen patients (56%) remained in the stable disease state and 8 patients progressed. The median overall survival was 9.0 months (95% CI 6.7~11.2). The median progression free survival was 3 months (95% CI 2.2~3.8). Hematological toxicities of grade 3 or 4 neutropenia, anemia and thrombocytopenia were absent. Non-hematological toxicities were grade 2 or 3 skin rashes in 10 (40.0%) patients and 1 (4.0%) patient and grade 3 nausea in 3 (12.0%) patients. No patient failed to continue chemotherapy due to any drug-related adverse events. CONCLUSION: The results suggest that ZD 1839 (IressaⓇ) monotherapy is effective and tolerable as a 3rd or 4th line salvage treatment for NSCLC patients refractory to previous chemotherapy regimens. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 502~506 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Non-small cell lung cancer | - |
dc.subject.MESH | ZD1839 (Iressa(R)) | - |
dc.title | The Effect of ZD 1839 (IressaⓇ) in the Treatment of Refractory Non Small Cell Lung Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yong Tai Kim | - |
dc.contributor.googleauthor | Chul Kim | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Kyung Young Chung | - |
dc.contributor.googleauthor | Kil Dong Kim | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Se Kyu Kim | - |
dc.contributor.googleauthor | Young Sam Kim | - |
dc.contributor.googleauthor | Nae Choon Yu | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | So Young Park | - |
dc.contributor.googleauthor | Joo Hyuk Sohn | - |
dc.identifier.doi | 10.4143/crt.2003.35.6.502 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00602 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 26680982 | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | ZD1839 (Iressa(R)) | - |
dc.contributor.alternativeName | Kim, Se Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Se Kyu | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 35 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 502 | - |
dc.citation.endPage | 506 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.35(6) : 502-506, 2003 | - |
dc.identifier.rimsid | 41411 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.